Also, it is still unclear what the efficacy is of [177Lu]Lu-PSMA in small tumor metastases (< 1 cm) since it is challenging to perform dosimetry on such small lesions and the currently available software methods are mainly appropriate to reliably assess dose to larger lesions. The gene discussed is FOLH1; the disease is neoplasm.